AOD-9604 in Marsac — Fat Loss Peptide Research Guide
AOD-9604 research guide for Marsac. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Marsac trying to locate AOD-9604, the first thing to know is that this compound is distributed via specialist online vendors. What this means for Marsac researchers is that your location matters far less than your ability to evaluate vendor quality — and those evaluation tools are available to every researcher. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis showing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. The sections below cover what Marsac researchers need to know about finding, evaluating, and storing AOD-9604 for scientific research use.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Marsac comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source AOD-9604 — Vendor Guide
Evaluating AOD-9604 vendors starts with the COA: locate the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not a structurally similar impurity — HPLC purity alone does not confirm what the compound actually is. Red flags in AOD-9604 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that do not include endotoxin results. For Marsac researchers making a first AOD-9604 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Marsac
COA-verified · International tracking · Research grade
All use of AOD-9604 in Marsac or anywhere must be research use only — this compound is not approved for human therapeutic use, and all handling should follow research laboratory protocols. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bac water. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. PubMed and bioRxiv represent the most comprehensive research databases for AOD-9604 research; focus on peer-reviewed publications with documented compound quality over case reports or anecdotal evidence.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
